The Manila Times

James M. O’Brien Appointed Chief Financial Officer at Mesoblast

Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that in connection with the Company’s transition to a fully ...

Protesters out in force to fight Bristol Airport's bid to expand

The first expansion from a capacity of nine million passengers a year to 12 million was, eventually, given the go-ahead in ...